Results 21 to 30 of about 105,631 (265)

Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.

Clinical Microbiology and Infection, 2020
OBJECTIVES To investigate the activity of ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Klebsiella pneumoniae (CRKP) and identify the resistance mechanisms before CAZ/AVI coming to Chinese market.
Ping Zhang, Qiucheng Shi, Hua-bing Hu, B. Hong, Xueqing Wu, Xiaoxing Du, M. Akova, Yunsong Yu   +7 more
semanticscholar   +1 more source

Cross resistance to cefiderocol and ceftazidime-avibactam in KPC beta-lactamase mutants and inoculum effect.

Clinical Microbiology and Infection, 2021
OBJECTIVES Ceftazidime-avibactam and cefiderocol are recently commercialized molecules active against highly drug-resistant bacteria, including carbapenem-resistant Enterobacteriaceae. Resistant mutants to ceftazidime-avibactam were described and notably
C. Hobson, A. Cointe, H. Jacquier, Alaksh Choudhury, M. Magnan, C. Courroux, O. Tenaillon, S. Bonacorsi, A. Birgy   +8 more
semanticscholar   +1 more source

In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019.

Diagnostic microbiology and infectious disease, 2022
ATLAS (Antimicrobial Testing Leadership and Surveillance) detects trends in multi-drug resistance longitudinally over time. In the present study, the in vitro activity of ceftazidime-avibactam and comparators was analyzed against Escherichia coli (n ...
Y. Bakthavatchalam, Abhisek Routray, A. Mane, S. Kamat, Animesh Gupta, A. Bari, A. Rohit, A. Poojary, D. Mukherjee, N. Sethuraman, N. Munshi, Sweta Shah, V. Balaji, Y. Gupta   +13 more
semanticscholar   +1 more source

Predatory Bacteria: A Potential Ally against Multidrug-Resistant Gram-Negative Pathogens [PDF]

, 2013
Multidrug-resistant (MDR) Gram-negative bacteria have emerged as a serious threat to human and animal health. Bdellovibrio spp. and Micavibrio spp. are Gram-negative bacteria that prey on other Gram-negative bacteria.
A Dashiff, AJ Kallen, AM Rogosky, Axel Cloeckaert, D Kadouri, D Kadouri, Daniel E. Kadouri, E Jurkevitch, GB Tian, H Stolp, Kevin To, M Dwidar, MO Martin, NY Markelova, RE Sockett, RE Sockett, RM Klevens, Robert M. Q. Shanks, S Rendulic, VA Lambina, VA Lambina, Y Davidov, Y Davidov, Y Doi, YA Kim, Yohei Doi, Z Wang   +26 more
core   +3 more sources

Long term physicochemical stability study of novel ophthalmic formulations combining ceftazidime and vancomycin with and without cyclodextrins

Pharmaceutical Technology in Hospital Pharmacy, 2023
Ceftazidime (CZ) and Vancomycin (VM) are used to treat bacterial keratitis; however, their physicochemical incompatibility does not allow their co-administration.
Plaidy Pauline, Bouattour Yassine, Yessaad Mouloud, Sautou Valérie, Chennell Philip   +4 more
doaj   +1 more source

Real-life comparison of three intravitreal antibiotic drug regimens in endophthalmitis

Indian Journal of Ophthalmology, 2022
Purpose: Real-life comparison of three intravitreal drug regimens used in cases of endophthalmitis at a tertiary care center in India. Methods: In this prospective, comparative study, patients of bacterial endophthalmitis were grouped according to ...
Aafreen Bari, Rohan Chawla, Deepanshi Mishra, Ujjwalkumar Das, Nasiq Hasan, Gita Satpathy, T Velpandian, Shorya V Azad, Pradeep Venkatesh, Rajpal Vohra, Atul Kumar   +10 more
doaj   +1 more source

Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

Antimicrobial Agents and Chemotherapy, 2020
The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown.
Renee Ackley, Danya Roshdy, Jacqueline Meredith, S. Minor, W. Anderson, G. Capraro, C. Polk   +6 more
semanticscholar   +1 more source

The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa

European Journal of Clinical Microbiology and Infectious Diseases, 2021
The cephalosporin-β-lactamase-inhibitor-combinations, ceftolozane/tazobactam and ceftazidime/avibactam, have revolutionized treatment of carbapenem-resistant Pseudomonas aeruginosa (CR-PA).
C. Gill, Elif Aktaþ, W. Alfouzan, L. Bourassa, A. Brink, C. Burnham, R. Cantón, Y. Carmeli, M. Falcone, C. Kiffer, A. Marchese, Octavio Martinez, S. Pournaras, M. Satlin, H. Seifert, A. Thabit, K. Thomson, M. Villegas, D. Nicolau   +18 more
semanticscholar   +1 more source

An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis [PDF]

, 2015
BACKGROUND: Several cases of Burkholderia pseudomallei infection in CF have been previously reported. We aimed to identify all cases globally, risk factors for acquisition, clinical consequences, and optimal treatment strategies.
Bell, SC, Currie, BJ, Geake, JB, Reid, DW   +3 more
core   +1 more source

Hydrolysis of cefazolin by enzymes produced by Pseudomonas aeruginosa after exposure to ceftazidime in vitro [PDF]

Vojnosanitetski Pregled, 2009
Background/Aim. Sometimes resistance of Pseudomonas aeruginosa (Ps. aeruginosa) is developed during antibiotic treatment, in spite of the initial susceptibility in vitro. The aim of this study was to use an in vitro model for the study of the development
Papaioannidou Paraskevi, Nitsas Vassilios, Mirtsou-Fidani Vassiliki   +2 more
doaj   +1 more source